MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Experience with utilization of rytary in the clinical setting
Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients
Objective: To assess the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on activities of daily…Comorbid conditions associated with Parkinson´s disease: A longitudinal study
Objective: (1)To study what comorbid conditions were present at baseline and 3 years later in a cohort of Spanish PD patients and (2) to analyze…Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets
Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients
Objective: To determine whether levodopa-carbidopa intestinal gel (LCIG) infusion is able to improve freezing of gait (FOG) in advanced Parkinson's disease (PD) patients. Background: FOG…Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients
Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…DBS related on-state freezing of gait – A case series
Objective: To present the first ever case series of on-state freezing of gait (FOG) after DBS surgery using dose-cycle gait evaluation. Background: FOG is categorized…Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease
Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.